GSK’s Quest to Bring Myeloma Drug Back to the Market Stops for a Data Drop at ASCO
GSK’s Blenrep has pivotal clinical trial results showing the multiple myeloma therapy reduced the risk of disease progression or death by nearly 50%. The results were presented Sunday during the annual meeting of the America Society of Clinical Oncology.